Antiangiogenic treatment of ovarian cancer patients

Abstract

According to 2007 American Cancer Society statistics, ovarian cancer is recognized as the most lethal gynecologic cancer. Standard treatment includes surgery and chemotherapy based on platinum derivatives and taxanes. However, treatment outcomes are not satisfactory because most patients develope cytostatic treatment resistant progressive disease. Searching for new strategies for ovarian cancer patients is thus warranted. Angiogenesis is one of the most important mechanisms responsible for cancer progression, while it is important in ovarian physiology as well. This review highlights the results of the latest clinical studies of antiangiogenic agents in ovarian cancer and discusses the perspectives for future clinical trials.